BHVN
Biohaven Ltd.
Price Chart
Latest Quote
$13.62
+1.53 (+12.66%)
Current Price
| Previous Close | $12.09 |
| Open | $13.16 |
| Day High | $13.97 |
| Day Low | $12.97 |
| Volume | 6,979,544 |
Stock Information
| Shares Outstanding | 150.56M |
| Total Debt | $286.18M |
| Cash Equivalents | $347.82M |
| Net Income | $-647.68M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.05B |
| EPS (TTM) | $-5.57 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.76B |
| Income | $-647.68M |
| Book/sh | $0.86 |
| Cash/sh | $2.31 |
| Employees | 274 |
Financial Ratios
| Quick Ratio | 6.68 |
| Current Ratio | 7.41 |
| Debt/Eq | 220.99 |
Returns & Margins
| ROA | -83.38% |
| ROE | -333.00% |
Ownership
| Insider Ownership | 11.08% |
| Institutional Ownership | 97.64% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.97 |
| P/B | 15.84 |
Analyst Data
| Recommendation | buy |
| Target Price | $21.71 |
Technical Indicators
| SMA20 | $10.94 |
| SMA50 | $10.20 |
| SMA200 | $11.58 |
| RSI | 72.35 |
| ATR | 1.0376 |
| Shares Float | 124.00M |
| Short Float | 21.47% |
| Short Ratio | 10.67 |
| Volatility | 3.31 |
| Rel Volume | 2.08 |
Performance History
| Week | +23.04% |
| Month | +60.42% |
| Quarter | +49.83% |
| 6 Months | +20.74% |
| YTD | +25.65% |
| Year | -10.28% |
| 3 Years | -43.16% |
| 10 Years | +90.87% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $13.62 | 6,980,100 |
| 2026-06-16 | $12.09 | 2,375,000 |
| 2026-06-15 | $12.14 | 4,471,500 |
| 2026-06-12 | $11.28 | 2,361,100 |
| 2026-06-11 | $11.37 | 4,385,600 |
| 2026-06-10 | $11.07 | 3,936,900 |
| 2026-06-09 | $11.09 | 3,772,700 |
| 2026-06-08 | $11.12 | 2,281,300 |
| 2026-06-05 | $10.80 | 2,036,000 |
| 2026-06-04 | $11.40 | 3,427,000 |
| 2026-06-03 | $10.81 | 3,114,500 |
| 2026-06-02 | $10.13 | 2,330,000 |
| 2026-06-01 | $11.43 | 2,701,900 |
| 2026-05-29 | $11.01 | 4,891,500 |
| 2026-05-28 | $10.24 | 4,471,700 |
| 2026-05-27 | $11.29 | 4,784,200 |
| 2026-05-26 | $10.07 | 2,216,100 |
| 2026-05-22 | $9.45 | 1,439,400 |
| 2026-05-21 | $9.48 | 2,157,800 |
| 2026-05-20 | $8.85 | 2,903,700 |
| 2026-05-19 | $8.39 | 1,486,300 |
| 2026-05-18 | $8.49 | 2,105,900 |
About Biohaven Ltd.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
đ° Latest News
Biohaven (BHVN) Climbs 12.66% Ahead of Pipeline Updates
Insider Monkey âĸ 2026-06-18T00:02:37Z
Rapport âfully preparedâ to launch seizure drug solo, CEO says
BioPharma Dive âĸ 2026-06-12T09:31:14Z
Is Biohaven (BHVN) Quietly Reframing Its Investment Story Around Brain Energy and Precision Immunology?
Simply Wall St. âĸ 2026-06-08T19:10:56Z
Biohaven (BHVN) Valuation Check After New R&D Milestones In Immunology Neuroscience And Metabolic Programs
Simply Wall St. âĸ 2026-06-07T21:17:51Z
Is Biohaven (BHVN) the Best Stock That Have the Potential to Rise 1000%?
Insider Monkey âĸ 2026-06-05T21:03:52Z
Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?
Zacks âĸ 2026-06-05T15:30:31Z
Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?
Zacks âĸ 2026-06-04T15:30:22Z
Biohaven (BHVN) Is Up 9.1% After Narrower Q1 Loss And New Mixed Shelf Registration - What's Changed
Simply Wall St. âĸ 2026-05-06T23:15:32Z
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why
Zacks âĸ 2026-05-05T16:00:02Z
A Look At Biohaven (BHVN) Valuation After Narrower Q1 Loss And New Pivotal Trial And Funding Plans
Simply Wall St. âĸ 2026-05-05T04:35:51Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $745,378,000 | $885,111,000 | $436,051,000 | $567,932,000 |
| Other Income Expense | $7,998,000 | $39,424,000 | $26,500,000 | $-1,909,000 |
| Other Non Operating Income Expenses | $7,998,000 | $39,424,000 | $26,500,000 | $-1,909,000 |
| Operating Expense | $745,378,000 | $885,111,000 | $436,051,000 | $567,932,000 |
| General And Administrative Expense | $110,313,000 | $89,240,000 | $62,770,000 | $130,860,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-738,822,000 | $-846,422,000 | $-408,168,000 | $-570,279,000 |
| Normalized Income | $-738,822,000 | $-846,422,000 | $-408,168,000 | $-570,279,000 |
| Net Income From Continuing And Discontinued Operation | $-738,822,000 | $-846,422,000 | $-408,168,000 | $-570,279,000 |
| Total Operating Income As Reported | $-745,378,000 | $-885,111,000 | $-436,051,000 | $-567,932,000 |
| Net Income Common Stockholders | $-738,822,000 | $-846,422,000 | $-408,168,000 | $-570,279,000 |
| Net Income | $-738,822,000 | $-846,422,000 | $-408,168,000 | $-570,279,000 |
| Net Income Including Noncontrolling Interests | $-738,822,000 | $-846,422,000 | $-408,168,000 | $-570,279,000 |
| Net Income Continuous Operations | $-738,822,000 | $-846,422,000 | $-408,168,000 | $-570,279,000 |
| Pretax Income | $-737,380,000 | $-845,687,000 | $-409,551,000 | $-569,841,000 |
| Operating Income | $-745,378,000 | $-885,111,000 | $-436,051,000 | $-567,932,000 |
| Earnings From Equity Interest | - | - | $0 | $0 |
| Per Share | ||||
| Diluted EPS | $-6.86 | $-9.28 | $-5.73 | $-12.75 |
| Basic EPS | $-6.86 | $-9.28 | $-5.73 | $-12.75 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-735,456,000 | $-877,256,000 | $-429,139,000 | $-566,546,000 |
| Reconciled Depreciation | $9,922,000 | $7,855,000 | $6,912,000 | $1,386,000 |
| EBITDA (Bullshit earnings) | $-735,456,000 | $-877,256,000 | $-429,139,000 | $-566,546,000 |
| EBIT | $-745,378,000 | $-885,111,000 | $-436,051,000 | $-567,932,000 |
| Diluted Average Shares | $107,624,885 | $91,234,337 | $71,200,527 | $44,741,316 |
| Basic Average Shares | $107,624,885 | $91,234,337 | $71,200,527 | $44,741,316 |
| Diluted NI Availto Com Stockholders | $-738,822,000 | $-846,422,000 | $-408,168,000 | $-570,279,000 |
| Tax Provision | $1,442,000 | $735,000 | $-1,383,000 | $438,000 |
| Research And Development | $635,065,000 | $795,871,000 | $373,281,000 | $437,072,000 |
| Selling General And Administration | $110,313,000 | $89,240,000 | $62,770,000 | $130,860,000 |
| Other Gand A | $110,313,000 | $89,240,000 | $62,770,000 | $130,860,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $32,282,000 | $403,646,000 | $408,185,000 | $518,981,000 |
| Total Assets | $451,447,000 | $615,107,000 | $513,212,000 | $661,783,000 |
| Total Non Current Assets | $83,118,000 | $76,635,000 | $70,766,000 | $74,815,000 |
| Other Non Current Assets | $2,306,000 | $3,134,000 | $2,400,000 | $2,585,000 |
| Goodwill And Other Intangible Assets | $19,790,000 | $19,790,000 | $19,790,000 | $19,790,000 |
| Other Intangible Assets | $18,400,000 | $18,400,000 | $18,400,000 | $18,400,000 |
| Current Assets | $368,329,000 | $538,472,000 | $442,446,000 | $586,968,000 |
| Other Current Assets | $2,170,000 | $3,105,000 | $12,133,000 | $19,331,000 |
| Prepaid Assets | $47,022,000 | $49,376,000 | $35,242,000 | $20,945,000 |
| Cash Cash Equivalents And Short Term Investments | $319,137,000 | $485,991,000 | $381,819,000 | $465,341,000 |
| Cash And Cash Equivalents | $229,957,000 | $99,134,000 | $248,402,000 | $204,877,000 |
| Receivables | - | $2,597,000 | $13,252,000 | $46,139,000 |
| Taxes Receivable | - | $2,597,000 | $13,252,000 | $46,139,000 |
| Restricted Cash | - | - | $0 | $35,212,000 |
| Cash Financial | - | - | - | - |
| Debt | ||||
| Net Debt | $8,943,000 | - | - | - |
| Total Debt | $284,614,000 | $36,584,000 | $30,877,000 | $33,600,000 |
| Long Term Debt And Capital Lease Obligation | $278,858,000 | $32,782,000 | $27,569,000 | $30,581,000 |
| Long Term Debt | $238,900,000 | - | - | - |
| Current Debt And Capital Lease Obligation | $5,756,000 | $3,802,000 | $3,308,000 | $3,019,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $399,375,000 | $191,671,000 | $85,237,000 | $123,012,000 |
| Total Non Current Liabilities Net Minority Interest | $283,441,000 | $37,445,000 | $29,814,000 | $32,991,000 |
| Other Non Current Liabilities | $4,583,000 | $4,663,000 | $2,245,000 | $2,410,000 |
| Current Liabilities | $115,934,000 | $154,226,000 | $55,423,000 | $90,021,000 |
| Other Current Liabilities | $42,710,000 | $84,710,000 | - | $11,715,000 |
| Payables And Accrued Expenses | $50,687,000 | $65,560,000 | $52,115,000 | $72,399,000 |
| Payables | $11,643,000 | $18,029,000 | $15,577,000 | $45,915,000 |
| Accounts Payable | $11,643,000 | $18,029,000 | $15,577,000 | $10,703,000 |
| Equity | ||||
| Common Stock Equity | $52,072,000 | $423,436,000 | $427,975,000 | $538,771,000 |
| Total Equity Gross Minority Interest | $52,072,000 | $423,436,000 | $427,975,000 | $538,771,000 |
| Stockholders Equity | $52,072,000 | $423,436,000 | $427,975,000 | $538,771,000 |
| Gains Losses Not Affecting Retained Earnings | $8,348,000 | $79,000 | $-65,000 | $284,000 |
| Other Equity Adjustments | $8,348,000 | $79,000 | $-65,000 | $284,000 |
| Retained Earnings | $-2,084,536,000 | $-1,345,714,000 | $-499,292,000 | $-91,124,000 |
| Other Equity Interest | - | - | - | - |
| Long Term Equity Investment | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $132,775,113 | $101,221,989 | $81,115,723 | $68,190,479 |
| Share Issued | $132,775,113 | $101,221,989 | $81,115,723 | $68,190,479 |
| Tangible Book Value | $32,282,000 | $403,646,000 | $408,185,000 | $518,981,000 |
| Invested Capital | $290,972,000 | $423,436,000 | $427,975,000 | $538,771,000 |
| Working Capital | $252,395,000 | $384,246,000 | $387,023,000 | $496,947,000 |
| Capital Lease Obligations | $45,714,000 | $36,584,000 | $30,877,000 | $33,600,000 |
| Total Capitalization | $290,972,000 | $423,436,000 | $427,975,000 | $538,771,000 |
| Additional Paid In Capital | $193,984,000 | $112,369,000 | $39,804,000 | $13,869,000 |
| Capital Stock | $1,934,276,000 | $1,656,702,000 | $887,528,000 | $615,742,000 |
| Common Stock | $1,934,276,000 | $1,656,702,000 | $887,528,000 | $615,742,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $39,958,000 | $32,782,000 | $27,569,000 | $30,581,000 |
| Current Capital Lease Obligation | $5,756,000 | $3,802,000 | $3,308,000 | $3,019,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $16,781,000 | $154,000 | $837,000 | $14,603,000 |
| Current Accrued Expenses | $39,044,000 | $47,531,000 | $36,538,000 | $26,484,000 |
| Goodwill | $1,390,000 | $1,390,000 | $1,390,000 | $1,390,000 |
| Net PPE | $61,022,000 | $53,711,000 | $48,576,000 | $52,440,000 |
| Accumulated Depreciation | $-16,126,000 | $-12,206,000 | $-8,283,000 | $-4,914,000 |
| Gross PPE | $77,148,000 | $65,917,000 | $56,859,000 | $57,354,000 |
| Leases | $2,697,000 | $824,000 | $802,000 | $0 |
| Other Properties | $45,058,000 | $36,709,000 | $31,943,000 | $37,574,000 |
| Machinery Furniture Equipment | $15,315,000 | $14,306,000 | $12,386,000 | $7,483,000 |
| Buildings And Improvements | $14,078,000 | $14,078,000 | $11,728,000 | $12,297,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $89,180,000 | $386,857,000 | $133,417,000 | $260,464,000 |
| Dueto Related Parties Current | - | - | $0 | $35,212,000 |
| Minority Interest | - | - | - | $0 |
| Investments And Advances | - | - | - | $0 |
| Other Investments | - | - | - | $0 |
| Land And Improvements | - | - | - | $12,297,000 |
| Construction In Progress | - | - | - | - |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-610,153,000 | $-586,502,000 | $-334,773,000 | $-338,763,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-609,438,000 | $-582,453,000 | $-331,725,000 | $-297,689,000 |
| Cash Flow From Continuing Operating Activities | $-609,438,000 | $-582,453,000 | $-331,725,000 | $-297,689,000 |
| Operating Gains Losses | $9,426,000 | $98,861,000 | - | $93,747,000 |
| Investing Activities | ||||
| Capital Expenditure | $-715,000 | $-4,049,000 | $-3,048,000 | $-41,074,000 |
| Investing Cash Flow | $300,561,000 | $-244,974,000 | $129,830,000 | $-304,790,000 |
| Cash Flow From Continuing Investing Activities | $300,561,000 | $-244,974,000 | $129,830,000 | $-304,790,000 |
| Net Other Investing Changes | $-1,849,000 | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $189,175,000 | $666,165,000 | $243,225,000 | $283,804,000 |
| Financing Cash Flow | $439,117,000 | $677,774,000 | $211,908,000 | $767,597,000 |
| Cash Flow From Continuing Financing Activities | $439,117,000 | $677,774,000 | $211,908,000 | $767,597,000 |
| Net Other Financing Charges | $-1,891,000 | $108,000 | $-36,012,000 | $483,342,000 |
| Net Common Stock Issuance | $189,175,000 | $666,165,000 | $243,225,000 | $283,804,000 |
| Common Stock Issuance | $189,175,000 | $666,165,000 | $243,225,000 | $283,804,000 |
| Other | ||||
| Issuance Of Debt | $250,000,000 | $0 | $0 | - |
| Interest Paid Supplemental Data | $216,000 | $125,000 | $0 | $0 |
| Income Tax Paid Supplemental Data | $133,000 | - | - | $38,165,000 |
| End Cash Position | $232,779,000 | $102,542,000 | $252,120,000 | $242,604,000 |
| Beginning Cash Position | $102,542,000 | $252,120,000 | $242,604,000 | $77,057,000 |
| Effect Of Exchange Rate Changes | $-3,000 | $75,000 | $-497,000 | $429,000 |
| Changes In Cash | $130,240,000 | $-149,653,000 | $10,013,000 | $165,118,000 |
| Proceeds From Stock Option Exercised | $1,833,000 | $11,501,000 | $4,695,000 | $451,000 |
| Net Issuance Payments Of Debt | $250,000,000 | $0 | $0 | - |
| Net Long Term Debt Issuance | $250,000,000 | $0 | $0 | - |
| Long Term Debt Issuance | $250,000,000 | $0 | $0 | - |
| Net Investment Purchase And Sale | $303,125,000 | $-241,316,000 | $132,878,000 | $-263,716,000 |
| Sale Of Investment | $570,000,000 | $504,364,000 | $326,999,000 | $0 |
| Purchase Of Investment | $-266,875,000 | $-745,680,000 | $-194,121,000 | $-263,716,000 |
| Net Intangibles Purchase And Sale | $0 | $391,000 | $0 | $-35,000,000 |
| Sale Of Intangibles | $0 | $391,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-715,000 | $-4,049,000 | $-3,048,000 | $-6,074,000 |
| Purchase Of PPE | $-715,000 | $-4,049,000 | $-3,048,000 | $-6,074,000 |
| Change In Working Capital | $1,357,000 | $16,811,000 | $24,613,000 | $-28,604,000 |
| Change In Payables And Accrued Expense | $-2,174,000 | $8,768,000 | $-2,563,000 | $12,732,000 |
| Change In Accrued Expense | $4,212,000 | $8,058,000 | $-7,437,000 | $6,804,000 |
| Change In Payable | $-6,386,000 | $710,000 | $4,874,000 | $5,928,000 |
| Change In Account Payable | $-6,386,000 | $710,000 | $4,874,000 | $5,928,000 |
| Change In Prepaid Assets | $3,531,000 | $8,043,000 | $27,176,000 | $-41,336,000 |
| Other Non Cash Items | $5,018,000 | $68,479,000 | $16,131,000 | $2,505,000 |
| Stock Based Compensation | $112,361,000 | $71,963,000 | $28,787,000 | $193,556,000 |
| Unrealized Gain Loss On Investment Securities | $-8,700,000 | $0 | $0 | - |
| Depreciation Amortization Depletion | $9,922,000 | $7,855,000 | $6,912,000 | $1,386,000 |
| Depreciation And Amortization | $9,922,000 | $7,855,000 | $6,912,000 | $1,386,000 |
| Gain Loss On Investment Securities | $9,426,000 | $88,050,000 | - | - |
| Gain Loss On Sale Of PPE | $0 | $10,811,000 | $0 | $93,747,000 |
| Net Income From Continuing Operations | $-738,822,000 | $-846,422,000 | $-408,168,000 | $-570,279,000 |
| Purchase Of Intangibles | - | $0 | $0 | $-35,000,000 |
| Asset Impairment Charge | - | $0 | $0 | $10,000,000 |
| Net Business Purchase And Sale | - | - | $0 | $0 |
| Sale Of Business | - | - | $0 | $0 |
| Earnings Losses From Equity Investments | - | - | $0 | $0 |
| Change In Other Current Liabilities | - | - | - | $0 |
| Change In Other Current Assets | - | - | - | $0 |
Fetched: 2026-06-17